Want to see CCCC full AI Analyst Report?
Top Page
C4 Therapeutics
(NASDAQ:CCCC)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-41.04% Downside)
Action:Reiterated
Date:09/25/26
Overall score is held down primarily by weak financial performance—ongoing heavy losses and material cash burn alongside declining TTM revenue. Technicals also lean bearish with the stock trading below major moving averages, partially offset by oversold indicators. A positive clinical data update provides some support, but valuation remains hard to anchor given negative earnings and no dividend.
Positive Factors
Targeted protein degradation platform
The TORPEDO platform gives C4 Therapeutics a focused technology base for developing targeted protein degradation medicines across oncology and other diseases. Its ability to support internal programs and pharmaceutical collaborations can broaden potential applications and create multiple paths to future milestone or royalty revenue.
Negative Factors
Persistent operating losses
The company's revenue base is not yet sufficient to cover operating costs, producing substantial and persistent losses. This makes profitability a longer-dated objective and leaves results sensitive to spending levels, collaboration revenue timing, and the success of future clinical development.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted protein degradation platform
The TORPEDO platform gives C4 Therapeutics a focused technology base for developing targeted protein degradation medicines across oncology and other diseases. Its ability to support internal programs and pharmaceutical collaborations can broaden potential applications and create multiple paths to future milestone or royalty revenue.
Read all positive factors
C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$376.46M
Dividend YieldN/A
Average Volume (3M)2.37M
Price to Earnings (P/E)―
Beta (1Y)2.36
Revenue Growth2.33%
EPS Growth36.86%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding123,025,140
10 Day Avg. Volume2,724,588
30 Day Avg. Volume2,368,622
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue11.80
Enterprise Value/Gross Profit12.44
Enterprise Value/Ebitda-4.15
Forecast
1Y Price Target
$8.50Price Target Upside100.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.85
Revenue Forecast (FY)$26.42M
C4 Therapeutics Business Overview & Revenue Model
Company Description
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions incl...
How the Company Makes Money
C4 Therapeutics primarily generates revenue through collaboration and license agreements with larger pharmaceutical companies, rather than through product sales (as it is clinical-stage). Under these arrangements, the company can earn (1) upfront ...
C4 Therapeutics Financial Statement Overview
Summary
Income Statement
23
Negative
Balance Sheet
54
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.04M | 35.95M | 35.58M | 20.76M | 31.10M | 45.78M |
| Gross Profit | 33.24M | 27.97M | 35.58M | 13.02M | 31.10M | 45.78M |
| EBITDA | -99.71M | -102.91M | -103.37M | -127.96M | -124.28M | -80.25M |
| Net Income | -101.42M | -104.99M | -105.32M | -132.49M | -128.18M | -83.89M |
Balance Sheet | ||||||
| Total Assets | 359.40M | 359.07M | 349.60M | 376.45M | 430.84M | 506.76M |
| Cash, Cash Equivalents and Short-Term Investments | 253.66M | 248.54M | 244.90M | 253.68M | 276.15M | 309.28M |
| Total Debt | 56.86M | 59.98M | 65.76M | 70.98M | 87.15M | 42.88M |
| Total Liabilities | 112.14M | 102.49M | 133.62M | 130.34M | 141.61M | 117.16M |
| Stockholders Equity | 247.26M | 256.59M | 215.99M | 246.11M | 289.23M | 389.61M |
Cash Flow | ||||||
| Free Cash Flow | -85.39M | -99.30M | -65.34M | -108.55M | -111.44M | -88.24M |
| Operating Cash Flow | -84.87M | -98.69M | -65.16M | -106.84M | -105.94M | -86.97M |
| Investing Cash Flow | -75.31M | -8.60M | -51.27M | 158.35M | 58.42M | -189.34M |
| Financing Cash Flow | 160.63M | 126.40M | 45.34M | 45.49M | 1.15M | 171.40M |
C4 Therapeutics Technical Analysis
Neutral
4.24
Price Trends
3.42
Negative
3.66
Negative
3.18
Negative
Market Momentum
-0.08
Negative
48.48
Neutral
78.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Neutral. The current price of 4.24 is above the 20-day moving average (MA) of 2.99, above the 50-day MA of 3.42, and above the 200-day MA of 3.18, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 48.48 is Neutral, neither overbought nor oversold. The STOCH value of 78.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCCC.
C4 Therapeutics Risk Analysis
C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
C4 Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $42.52M | -1.12 | 248.50% | ― | ― | 36.06% | |
47 Neutral | $376.46M | -3.06 | -45.45% | ― | 2.33% | 36.86% | |
42 Neutral | $2.33B | -54.61 | -35.91% | ― | ― | 35.38% | |
42 Neutral | $20.78M | -0.88 | -60.32% | ― | ― | 71.26% | |
42 Neutral | $186.90M | -2.32 | -136.45% | ― | ― | -1475.42% |
* Healthcare Sector Average
CCCC
C4 Therapeutics
3.06
0.41
15.47%
SLS
SELLAS Life Sciences Group
11.54
9.60
494.85%
MCRB
Seres Therapeutics
2.09
-15.08
-87.83%
ELDN
Eledon Pharmaceuticals
2.30
-1.53
-39.95%
TVGN
Tevogen Bio Holdings
6.53
-24.86
-79.20%
ACTU
Actuate Therapeutics, Inc.
0.48
-6.80
-93.47%
C4 Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
C4 Therapeutics Reports New Cemsidomide Myeloma Data
Positive
Sep 25, 2026
On September 25, 2026, C4 Therapeutics presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and Phase 1b trial with elranatamab in relapsed or refractory multiple myeloma at the International Myeloma Society annual...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.